Europe Plasma Fractionation Market

Europe Plasma Fractionation Market Size (2024 to 2029)

The size of the Europe plasma fractionation market is estimated to be worth USD 6.53 billion in 2024 and USD 8.77 bn by 2029, growing at a CAGR of 6.10% from 2024 to 2029.

Plasma fractionation is a technique for extracting plasma derivatives using a separation method. Albumin and immunoglobulins are two examples of plasma derivates available on the market.

These products contain concentrated fractions of plasma protein, which are isolated from plasma obtained from many donors using fractionation. Plasma fractionation has become more popular as the older population has grown. This age group is particularly susceptible to various age-related disorders that necessitate various plasma protein therapies.

The growth of the European Plasma Fractionation Market is mainly driven by factors such as the increasing incidence of immune and bleeding disorders, the growing incidence of Alpha-1 Antitrypsin deficiency, and the rising use of immunoglobulins. Further, an increasingly aging population with related blood-related ailments is set to promote market growth. Additionally, the growing use of immunoglobulins in various therapeutic domains, the expanding elderly population coupled with the rising frequency of rare diseases, and an increasing number of plasma collection sites are expected to be driving the market expansion. Furthermore, the rising prevalence of chronic neurological disorders, rheumatoid arthritis, and osteoarthritis has contributed to a rise in people who require modern therapies.However, adverse reactions to plasma fractionation and transfer, high plasma product costs, ineffective reimbursement systems, and the rising use of recombinant alternatives are major market growth stumbling blocks.

Impact of COVID-19 on the European plasma fractionation market

Following the WHO’s declaration of COVID-19 as a pandemic, countries worldwide implemented statewide lockdowns to enforce social separation as a preventative precaution. In every industry, this causes disruption, limits, challenges, and adjustments. The pandemic influenced the plasma fractionation business as well. The COVID-19 pandemic has resulted in a decline in blood donations and plasma collection, hating market growth due to a shortage of raw materials. As the elective surgical procedure was postponed and care for other medical illnesses was similarly hampered, a loss in raw material supply was balanced by decreased demand for plasma derivatives at the commencement of nationwide lockdowns.

This research report on the European Plasma Fractionation Market has been segmented and sub-segmented into the following categories.

Europe Plasma Fractionation Market Analysis By Product 

• Albumin
• Immunoglobulin
• Factor VIII
• Protease Inhibitors

Europe Plasma Fractionation Market Analysis By Application 

• Neurology
• Hematology
• Rheumatology
• Pulmonology
• Immunology

Europe Plasma Fractionation Market Analysis By End User

• Hospitals
• Clinical Laboratories

Europe Plasma Fractionation Market Analysis By Country 

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Geographically, Europe comes second in terms of market share in the global market due to greater awareness of blood-related illnesses and the speedy availability of therapy in terms of plasma fractionation.

Furthermore, due to the rising occurrence of rare diseases in Europe, the region is expected to increase rapidly during the projection period. In addition, the market will benefit from significant investments in plasma fractionation systems.As part of developing plasma-derived therapy for treating the COVID-19 virus, the firms collaborate closely with hospitals. As a result, the hospitals and clinics segment is expected to occupy the greatest proportion of the global plasma fractionation market, based on the end-user. The expanding need for therapies for immunodeficiency disorders, the rising number of hospitals and healthcare expenditures, and the rising consumption of plasma-derived products by hospitals and clinics are all driving this segment’s rise. The market is divided into two sectors, the private sector, and the public sector.Due to the technical advancements, the rate of diagnosis of a variety of immunological illnesses has increased. Furthermore, due to the increased number of diagnosed patients, increased genetic research for characterizing and diagnosing immunodeficiency will increase the clinical need for immunoglobulins.The German plasma fractionation market is expected to lead the European market during the forecasting period.

KEY MARKET PLAYERS

A few of the noteworthy companies operating in the European plasma fractionation market profiled in the report are CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), Bio Products Laboratory (U.K.), Sanquin (Netherland), China Biologic Products, Inc. (China), Biotest AG (Germany), and Laboratoire Français du Fractionnement et des Biotechnologies (France).